Fierce Pharma Asia—Novartis reworks China ties; Neurocrine-Takeda med passes depression test; Enhertu nears key readout
Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. Neurocrine Biosciences is considering moving a depression drug candidate licensed from Takeda into phase 3 testing. AstraZeneca and Daiichi Sankyo…